Gemfibrozil improves postprandial hypertriglyceridemia in patients with isolated low HDL

Hania Kassem, Mira S. Zantout, Sami T. Azar

Research output: Contribution to journalArticle

Abstract

Aim: To assess the response of postprandial (PP) hypertriglyceridemia to genfibrozil in healthy male subjects with isolated low HDL-Cholesterol but without the metabolic syndrome (MS). Patients and methods: 14 male subjects with isolated low HDL (HDL-C ≥ 33), normal fasting triglycerides and LDL-C levels and without any feature of the MS, were studied. 13 male subjects with HDL-C > 38 mg/dl served as controls. They also had normal fasting triglycerides and LDL-C levels and without any feature of the MS. The 2 groups were statistically similar with respect to age, blood pressure, BMI, body fat composition, waist circumference, waist to hip ratio, fasting insulin, fasting and PP blood sugar, baseline fasting TG level and baseline LDL-C. Postprandial TG levels were measured at 2, 4, and 6 hours following a morning meal. Ten of the patients with PP hypertriglyceridemia were treated with gemfibrozil 600 mg PO twice/day for one month. Results: Patients had markedly higher levels of the peak PP TG at 4 hours compared to controls (296.0 ± 37.7 vs. 206.7 ± 29.9 mg/dl; P < 0.05) the other two postprandial levels were also higher in patients but the difference was not significant. Treatment with gemfibrozil significantly decreased the levels of fasting and postprandial TG and increased HDL-C by around 3.6 mg/dl (11.7%) without affecting LDL-C. Conclusion: Postprandial increase in serum TG may be present in patients with isolated HDL-C without the MS. Treatment of patients with PP hypertriglyceridemia with gemfibrozil improves the low HDL-C and postprandial rise in TG.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalLipid Insights
Volume4
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Gemfibrozil
Hypertriglyceridemia
Fasting
Blood pressure
HDL Cholesterol
Blood Glucose
Fats
Insulin
Waist-Hip Ratio
Breakfast
Waist Circumference
Body Composition
Chemical analysis
Adipose Tissue
Healthy Volunteers
Blood Pressure
low density lipoprotein triglyceride
oxidized low density lipoprotein
Therapeutics
Serum

Keywords

  • Gemfibrozil
  • Healthy
  • Low HDL-C
  • Male
  • Postprandial triglycerides
  • Triglycerides

ASJC Scopus subject areas

  • Biochemistry

Cite this

Gemfibrozil improves postprandial hypertriglyceridemia in patients with isolated low HDL. / Kassem, Hania; Zantout, Mira S.; Azar, Sami T.

In: Lipid Insights, Vol. 4, 2011, p. 1-5.

Research output: Contribution to journalArticle

@article{eac305ae347b4f77a87ec38a16262f14,
title = "Gemfibrozil improves postprandial hypertriglyceridemia in patients with isolated low HDL",
abstract = "Aim: To assess the response of postprandial (PP) hypertriglyceridemia to genfibrozil in healthy male subjects with isolated low HDL-Cholesterol but without the metabolic syndrome (MS). Patients and methods: 14 male subjects with isolated low HDL (HDL-C ≥ 33), normal fasting triglycerides and LDL-C levels and without any feature of the MS, were studied. 13 male subjects with HDL-C > 38 mg/dl served as controls. They also had normal fasting triglycerides and LDL-C levels and without any feature of the MS. The 2 groups were statistically similar with respect to age, blood pressure, BMI, body fat composition, waist circumference, waist to hip ratio, fasting insulin, fasting and PP blood sugar, baseline fasting TG level and baseline LDL-C. Postprandial TG levels were measured at 2, 4, and 6 hours following a morning meal. Ten of the patients with PP hypertriglyceridemia were treated with gemfibrozil 600 mg PO twice/day for one month. Results: Patients had markedly higher levels of the peak PP TG at 4 hours compared to controls (296.0 ± 37.7 vs. 206.7 ± 29.9 mg/dl; P < 0.05) the other two postprandial levels were also higher in patients but the difference was not significant. Treatment with gemfibrozil significantly decreased the levels of fasting and postprandial TG and increased HDL-C by around 3.6 mg/dl (11.7{\%}) without affecting LDL-C. Conclusion: Postprandial increase in serum TG may be present in patients with isolated HDL-C without the MS. Treatment of patients with PP hypertriglyceridemia with gemfibrozil improves the low HDL-C and postprandial rise in TG.",
keywords = "Gemfibrozil, Healthy, Low HDL-C, Male, Postprandial triglycerides, Triglycerides",
author = "Hania Kassem and Zantout, {Mira S.} and Azar, {Sami T.}",
year = "2011",
doi = "10.4137/LPI.S5722",
language = "English (US)",
volume = "4",
pages = "1--5",
journal = "Lipid Insights",
issn = "1178-6353",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Gemfibrozil improves postprandial hypertriglyceridemia in patients with isolated low HDL

AU - Kassem, Hania

AU - Zantout, Mira S.

AU - Azar, Sami T.

PY - 2011

Y1 - 2011

N2 - Aim: To assess the response of postprandial (PP) hypertriglyceridemia to genfibrozil in healthy male subjects with isolated low HDL-Cholesterol but without the metabolic syndrome (MS). Patients and methods: 14 male subjects with isolated low HDL (HDL-C ≥ 33), normal fasting triglycerides and LDL-C levels and without any feature of the MS, were studied. 13 male subjects with HDL-C > 38 mg/dl served as controls. They also had normal fasting triglycerides and LDL-C levels and without any feature of the MS. The 2 groups were statistically similar with respect to age, blood pressure, BMI, body fat composition, waist circumference, waist to hip ratio, fasting insulin, fasting and PP blood sugar, baseline fasting TG level and baseline LDL-C. Postprandial TG levels were measured at 2, 4, and 6 hours following a morning meal. Ten of the patients with PP hypertriglyceridemia were treated with gemfibrozil 600 mg PO twice/day for one month. Results: Patients had markedly higher levels of the peak PP TG at 4 hours compared to controls (296.0 ± 37.7 vs. 206.7 ± 29.9 mg/dl; P < 0.05) the other two postprandial levels were also higher in patients but the difference was not significant. Treatment with gemfibrozil significantly decreased the levels of fasting and postprandial TG and increased HDL-C by around 3.6 mg/dl (11.7%) without affecting LDL-C. Conclusion: Postprandial increase in serum TG may be present in patients with isolated HDL-C without the MS. Treatment of patients with PP hypertriglyceridemia with gemfibrozil improves the low HDL-C and postprandial rise in TG.

AB - Aim: To assess the response of postprandial (PP) hypertriglyceridemia to genfibrozil in healthy male subjects with isolated low HDL-Cholesterol but without the metabolic syndrome (MS). Patients and methods: 14 male subjects with isolated low HDL (HDL-C ≥ 33), normal fasting triglycerides and LDL-C levels and without any feature of the MS, were studied. 13 male subjects with HDL-C > 38 mg/dl served as controls. They also had normal fasting triglycerides and LDL-C levels and without any feature of the MS. The 2 groups were statistically similar with respect to age, blood pressure, BMI, body fat composition, waist circumference, waist to hip ratio, fasting insulin, fasting and PP blood sugar, baseline fasting TG level and baseline LDL-C. Postprandial TG levels were measured at 2, 4, and 6 hours following a morning meal. Ten of the patients with PP hypertriglyceridemia were treated with gemfibrozil 600 mg PO twice/day for one month. Results: Patients had markedly higher levels of the peak PP TG at 4 hours compared to controls (296.0 ± 37.7 vs. 206.7 ± 29.9 mg/dl; P < 0.05) the other two postprandial levels were also higher in patients but the difference was not significant. Treatment with gemfibrozil significantly decreased the levels of fasting and postprandial TG and increased HDL-C by around 3.6 mg/dl (11.7%) without affecting LDL-C. Conclusion: Postprandial increase in serum TG may be present in patients with isolated HDL-C without the MS. Treatment of patients with PP hypertriglyceridemia with gemfibrozil improves the low HDL-C and postprandial rise in TG.

KW - Gemfibrozil

KW - Healthy

KW - Low HDL-C

KW - Male

KW - Postprandial triglycerides

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=84858606112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858606112&partnerID=8YFLogxK

U2 - 10.4137/LPI.S5722

DO - 10.4137/LPI.S5722

M3 - Article

VL - 4

SP - 1

EP - 5

JO - Lipid Insights

JF - Lipid Insights

SN - 1178-6353

ER -